TRACON to Announce First Quarter 2022 Financial Results and Corporate Updates on May 11, 2022 | news

SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (Nasdaq: TCON), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics utilizing a cost-effective, CRO-independent product development platform in partnership with A former US company that develops and commercializes innovative products in the United States, today announced that it will report its first quarter 2022 financial and operating results after the US financial markets close on Wednesday, May 11, 2022. In addition, management will host a conference call to provide an update on the Company’s activities and to discuss financial results.

A replay of the webcast will be available on the website for 60 days.

About TRACON

TRACON develops targeted therapies for cancer using a capital-efficient, CRO-independent product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody delivered by rapid subcutaneous injection and being investigated in the pivotal ENVASARC study in sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships, leading regulatory and clinical development in the US, sharing the costs and risks of clinical development, and leading US commercialization. TRACON believes that in these partnerships it can serve as a solution for companies without clinical and commercial capabilities in the United States. To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.

Copyright 2022 GlobeNewswire, Inc.